Medivation (MDVN) Preclinical Excitement Seems To Be Bearing Fruit - Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
AstraZeneca (AZN) Considering Offer for Medivation (MDVN) - Times
April 18, 2016 7:14 AM EDTAstraZeneca (NYSE: AZN) has held internal talks and is looking very closely at an offer for Medivation (NASDAQ: MDVN), according to The Times.
Medivation (MDVN) Taps Session High
April 15, 2016 9:55 AM EDTMedivation (NASDAQ: MDVN) advanced Friday morning, rising 6%.
Leerink Highlights Top 10 Biopharma Stocks for Partnerships & Acquisitions
April 14, 2016 12:07 PM EDTIn addition to naming Acadia Pharma (NASDAQ: ACAD) one of his top partnership and acquisition (P&A) targets, as noted earlier, Leerink analyst Joseph Schwartz listed 9 other stocks on his Top 10 list. Below is a run-down of the others:
Akorn, Inc. (NASDAQ: AKRX) (Market Perform)
Rationale for P&A: "AKRX operates in generic segments with higher barriers... More
